HSV pre-clinical studies
During the past few months, the Company has continued to refine its course of developing applications for its core technology.Most significant is the pre-clinical program for an anti-viral HSV topical preparation.We have teamed-up with a group of leading herpes and STD investigators at a large academic medical center to conduct a comprehensive cell and animal study program designed to yield safety and efficacy data in preparation for an IND submission planned for March 2003 and subsequent human trials.

Target Validation Services
The Genomics field has expanded the number of potential drug targets to several thousand. The CytoGenix proprietary gene down-regulation system is a powerful tool in confirming gene target function.In July 2002, we inaugurated a service geared towards assisting pharmaceutical and biotech companies improve drug discovery efficiency.In addition to our work on in-house targets, we are conducting a pilot studies for several companies.For a fixed fee, we will knockdown a gene in a cell system.This will confirm the gene’s relevance to the disease of interest.Those genes found to be highly disease-related become targets for new drug or molecular therapies.